MAP2K7 and melanoma: Three patients with advanced BRAF+MEK inhibitor-resistant melanoma, who suffered from progression upon dabrafenib plus trametinib therapy, were treated with vorinostat (360 mg/day, orally), which suppressed SLC7A11 in taken biopsies.